

Adult-Onset Asthma Doubles Women's Heart Risks

BY MITCHEL L. ZOLER
Philadelphia Bureau

ORLANDO — Adult-onset asthma was linked to an almost twofold increased rate of coronary heart disease or stroke in women in a study with more than 15,000 people.

The mechanism behind this association is unknown but may be explained by an increased level of systemic inflammation in women with adult-onset asthma, Stephen Onufrak and his associates reported in a poster presented at a conference on cardiovascular disease epidemiology and prevention, sponsored by the American Heart Association.

Prior findings from other studies also supported links between asthma and atherosclerotic events, and showed that the association was strongest in women, said Mr. Onufrak, an epidemiologist at Emory University, Atlanta.

The study used data collected from 15,573 white and black persons who were enrolled in the Atherosclerosis Risk in Communities (ARIC) study during the period 1987-1989.

The group included nearly 7,000 men, of whom 6,594 had no asthma, 227 had asthma that began during childhood, and 146 had adult-onset asthma.

Also included were more than 8,600 women, with 8,093 who had no asthma, 214 who had childhood-onset asthma, and 299 whose asthma started after they were adults.

For this analysis, childhood asthma was defined as having its onset before age 21, and adult-onset asthma was defined as appearing at age 21 or after.

The researchers then analyzed the rates

of incident coronary heart disease or stroke during 12-14 years of follow-up based on asthma prevalence at baseline.

The hazard ratios were adjusted to account for baseline differences in several demographic and clinical variables, including age, race, body mass index, smoking history, hypertension, serum lipid levels, and physical activity.

The analyses showed that women with adult-onset asthma were 70% more likely to develop coronary artery disease and

79% more likely to have stroke, compared with women who did not report having asthma.

Both of these differences were statistically significant.

Compared with people with no asthma, no significant change was seen in the hazard ratios for coronary heart disease or stroke among women who reported having childhood asthma or among men with either adult-onset or childhood asthma (see box).

Another analysis focused exclusively on the men and women who had never smoked.


Again, those women with adult asthma had a statistically significant twofold increased risk of coronary heart disease or stroke, compared with those women without asthma.

There were no significant differences in outcome rates seen in women with childhood asthma or among men, the researchers reported. ■

Women with adult-onset asthma were 70% more likely to develop CAD and 79% more likely to have a stroke than nonasthmatic women.

supported links between asthma and atherosclerotic events, and showed that the association was strongest in women, said Mr. Onufrak, an epidemiologist at Emory University, Atlanta.

The study



Discover **Levemir**®:
a long-acting basal insulin
with a light touch

Levemir: for your patients who need a safe and effective way to improve A1C control

With proven reductions in A1C and FPG levels over time, Levemir can help your patients get to goal with up to 24 hours of glycemic control. Patients with diabetes can experience a consistent blood glucose response from injection to injection. Less weight gain was observed with Levemir in 12 of 12 clinical trials.* And Levemir is available in the Levemir® FlexPen®. FlexPen® is the world's #1 selling prefilled insulin pen.† So start your patients with diabetes on Levemir, and help them experience the light side of basal insulin.

Levemir is indicated for once- or twice-daily subcutaneous administration for the treatment of adult and pediatric patients with type 1 diabetes mellitus or adult patients with type 2 diabetes mellitus who require basal (long-acting) insulin for the control of hyperglycemia.

Important safety information
Levemir should not be diluted or mixed with any other insulin preparations.

Levemir is contraindicated in patients hypersensitive to insulin detemir or one of its excipients.

Hypoglycemia is the most common adverse effect of all insulin therapies, including Levemir. As with other insulins, the timing of hypoglycemic events may differ among various insulin preparations. Glucose monitoring is recommended for all patients with diabetes. Any change of insulin dose should be made cautiously

and only under medical supervision. Concomitant oral antidiabetes treatment may require adjustment.

Levemir is not to be used in insulin infusion pumps. Inadequate dosing or discontinuation of treatment may lead to hyperglycemia and, in patients with type 1 diabetes, diabetic ketoacidosis. Insulin may cause sodium retention and edema, particularly if previously poor metabolic control is improved by intensified insulin therapy. Dose and timing of administration may need to be adjusted to reduce the risk of hypoglycemia in patients being switched to Levemir from other intermediate or long-acting insulin preparations. The dose of Levemir may need to be adjusted in patients with renal or hepatic impairment.

Other adverse events commonly associated with insulin therapy may include injection site reactions (on average, 3% to 4% of patients

in clinical trials) such as lipodystrophy, redness, pain, itching, hives, swelling, and inflammation.

*Whether these observed differences represent true differences in the effects of Levemir and NPH insulin is not known, since these trials were not blinded and the protocols (eg, diet and exercise instructions and monitoring) were not specifically directed at exploring hypotheses related to weight effects of the treatments compared. The clinical significance of the observed differences in weight has not been established.



Levemir®
insulin detemir (rDNA origin) injection
Lighter years ahead

Reference: 1. IMS Health, IMS MIDAS [12 months ending September 2005]. Please see brief summary of Prescribing Information on adjacent page. FlexPen and Levemir are registered trademarks of Novo Nordisk A/S. © 2006 Novo Nordisk Inc. 131007 September 2006



ELSEVIER GLOBAL MEDICAL NEWS

